Density 1.22 g/cm³ Appearance Bright yellow crystals | Boiling point 304.5 °C | |
 | ||
Menadione is an organic compound with the formula C6H4(CO)2C2H(CH3). It is an analog of 1,4-naphthoquinone with a methyl group in the 2-position. It is occasionally used as a nutritional supplement because of its vitamin K activity.
Contents
Terminology
It is sometimes called vitamin K3, although derivatives of naphthoquinone are not naturally occurring chemicals and therefore do not qualify as vitamins, and without the side chain in the 2-position they cannot exert all the functions of the K vitamins. Menadione is metabolized by the human body into K2 which uses alkylation to yield menaquinones (MK-n, n=1-13; K2 vitamers), hence is better classified as a provitamin.
It is also known as "menaphthone".
Uses
It is an intermediate in the chemical synthesis of vitamin K by first reduction to the diol menadiol, which is suscepible to coupling to the phytol.
Despite the fact that it can serve as a precursor to various types of vitamin K, menadione is generally not used as a nutritional supplement in economically developed countries. Menadione for human use at pharmaceutical strength is available in some countries with large lower income populations. It is used in the treatment of hypoprothrombinemia outside of the United States.
Toxicity
Large doses of menadione have been reported to cause adverse outcomes including hemolytic anemia due to glucose-6-phosphate dehydrogenase deficiency, neonatal brain or liver damage, or neonatal death in some rare cases. In the United States, menadione supplements are banned by the U.S. Food and Drug Administration because of their potential toxicity in human use.
Low-dose menadione is still used as an inexpensive micronutrient for livestock in many countries. Forms of menadione are also included in some pet foods in developed countries as a source of vitamin K. These doses have yielded no reported cases of toxicity from menadione in livestock or pets.
Research
Menadione in combination with vitamin C has been investigated for the treatment for prostate cancer.
A menadione topical lotion reduces epidermal growth factor receptor inhibitor-related side effects by the prevention of skin toxicities that result from inhibition of protein kinases by drugs such as erlotinib (Tarceva) and cetuximab (Erbitux).